Skip to NavigationSkip to content

Roche's Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

Published on 29/05/18 at 11:28am

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the drug met its co-primary endpoints when used in combination with carboplatin and Abraxane chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer (NCSLC).

The Phase 3 results showed that the Tecentriq/chemotherapy combo “significantly” improved overall survival and reduced the risk of disease progression or death compared to chemotherapy alone. The therapy’s safety profile was also found to be consistent with previous data. A full report of the findings will be announced at an upcoming oncology congress.  

“The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced non-squamous non-small cell lung cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We will share these results with global health authorities with the goal of bringing this potential treatment option to people with this disease.”

The new findings mark the third positive study of Tecentriq’s effectiveness alone or as a combination in the treatment of NSCLC, another key step in its pursuit of MSD’s Keytruda and BMS’ Opdivo. Roche currently has eight trials underway for the drug in the lung cancer space.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches